Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. ACN
3. NVDA
4. USO
5. GOOGL
6. APGE
7. MU
8. DFTX
9. HOOD
10. LLY

Go back to Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity
(NASDAQ: CRBP) Delayed: 8.35 +0.09 (1.09%)
Previous Close $8.26    52 Week High $10.78 
Open $8.28    52 Week Low $1.01 
Day High $8.62    P/E N/A 
Day Low $8.26    EPS $0.00 
Volume 180,975